Danaher (NYSE:DHR) Lowered to “Hold” Rating by StockNews.com

Danaher (NYSE:DHR) was downgraded by StockNews.com from a “buy” rating to a “hold” rating in a note issued to investors on Saturday.

DHR has been the topic of several other research reports. Stifel Nicolaus lifted their price objective on shares of Danaher from $250.00 to $265.00 and gave the stock a “hold” rating in a research note on Wednesday, October 23rd. Stephens reaffirmed an “overweight” rating and set a $315.00 target price on shares of Danaher in a report on Wednesday, October 23rd. TD Cowen upped their price objective on shares of Danaher from $310.00 to $315.00 and gave the company a “buy” rating in a research note on Wednesday, October 23rd. Barclays reduced their price target on shares of Danaher from $285.00 to $275.00 and set an “equal weight” rating for the company in a research report on Wednesday, October 23rd. Finally, Raymond James decreased their target price on Danaher from $310.00 to $300.00 and set an “outperform” rating for the company in a research report on Wednesday, October 23rd. Five research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to MarketBeat.com, Danaher currently has an average rating of “Moderate Buy” and an average price target of $287.95.

Danaher Price Performance

NYSE DHR opened at $234.99 on Friday. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 0.32. The company has a 50-day moving average price of $247.62 and a two-hundred day moving average price of $257.62. The stock has a market cap of $169.73 billion, a price-to-earnings ratio of 44.85, a price-to-earnings-growth ratio of 4.33 and a beta of 0.83. Danaher has a 52 week low of $222.53 and a 52 week high of $281.70.

Danaher (NYSE:DHR) last released its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, beating the consensus estimate of $1.57 by $0.14. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The firm had revenue of $5.80 billion for the quarter, compared to analysts’ expectations of $5.59 billion. During the same quarter last year, the company earned $2.02 EPS. Danaher’s quarterly revenue was up 3.1% on a year-over-year basis. Analysts forecast that Danaher will post 7.5 EPS for the current year.

Institutional Trading of Danaher

Several institutional investors and hedge funds have recently made changes to their positions in DHR. CarsonAllaria Wealth Management Ltd. acquired a new stake in Danaher during the 2nd quarter worth $25,000. nVerses Capital LLC acquired a new stake in shares of Danaher in the 2nd quarter valued at about $25,000. Teachers Insurance & Annuity Association of America bought a new position in shares of Danaher during the third quarter worth about $39,000. MidAtlantic Capital Management Inc. acquired a new stake in Danaher in the 3rd quarter valued at approximately $40,000. Finally, FSA Wealth Management LLC bought a new stake in shares of Danaher in the third quarter worth $50,000. Institutional investors own 79.05% of the company’s stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.